Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Not yet recruiting2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

active_not_recruiting125%
not_yet_recruiting250%
recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_3

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

NCT07461454
recruitingphase_2

A Study of YL202 in Patients With Advanced Solid Tumors

NCT07202364
not_yet_recruitingphase_3

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

NCT07416994
active_not_recruitingphase_1

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

NCT05653752

Clinical Trials (4)

Showing 4 of 4 trials
NCT07461454Phase 3

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Not Yet Recruiting
NCT07202364Phase 2

A Study of YL202 in Patients With Advanced Solid Tumors

Recruiting
NCT07416994Phase 3

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT05653752Phase 1

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4